FormWeb • Encorafenib

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search by class Show Therapeutic Classes

Webpage Links

Add Formweb to your mobile device

Android iOS

Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

Encorafenib

Encorafenib

Non-formulary Anti-Neoplastic Drug Formulary
HAZ-MED: Table 1

Drug Name	Form	Strength	Formulary Unrestricted	Formulary Restricted	Non-Formulary	Interchange
Braftovi	CAPSULE, ORAL	50 mg, 75 mg

Comments:

At Huntsville Main/W&C/Madison, orders for this medication should be rejected and reviewed by an oncology clinical specialist or an oncology pool member (see second page of the document "Hormone Therapies and Guidance on Oral Chemotherapy")

Inpatients may use home supply. Defer initiation until after patient discharge.

Reviewed: February 2024

Encorafenib (Braftovi)

Last updated: Mar. 11, 2025

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.